Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach
Journal of Nursing Scholarship2023Vol. 55(3), pp. 655–664
Citations Over TimeTop 11% of 2023 papers
Abstract
One of the most robust tools to combat opioid overdose deaths is buprenorphine, a partial opioid agonist, and gold standard medication treatment for OUD, but only 5% of the prescribing workforce possess the required Drug Enforcement Agency (DEA) X waiver. A growing body of evidence demonstrates that Advanced Practice Registered Nurses are accelerating the growth in waiver update and buprenorphine use, despite the considerable barriers and limitations described in this policy analysis.
Related Papers
- → Opioid Use Disorder Education for Students and the Future of Opioid Overdose Treatment(2022)2 cited
- → EPH251 Neighborhood Characteristics of Availability of Buprenorphine-Prescribing Clinicians and X-Waivered Clinicians(2023)1 cited
- → Initiation of Extended-release Depot Buprenorphine in a Patient Subject to a Community Treatment Order for Both Antipsychotic and Opioid Agonist Treatments(2023)1 cited
- → Can buprenorphine be used for opioid use disorder during pregnancy?(2021)
- → Opioid Use Disorder Education for Students and the Future of Opioid Overdose Treatment (Preprint)(2022)